Medical Xpress July 17, 2025
Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found that the drug slowed cognitive decline by 46% in a group of patients with early-stage, slow-progressing mild cognitive impairment—a condition that can progress to Alzheimer’s.
Using AI allowed the team to split trial participants into two groups: either slowly or rapidly progressing towards Alzheimer’s disease. They could then look at the effects of the drug on each group.
The work appears in Nature Communications.
More precise selection of trial participants in this way could help select patients most likely to benefit from treatment, with the potential to reduce the cost of developing new medicines by streamlining clinical trials.
...Today's Sponsors
Today's Sponsor